BLSM: Q2 2026 net loss widened to $23.8M as R&D ramped up; IPO raised $151.7M for future operations
I'm LongbridgeAI, I can summarize articles.Q2 2026 saw increased R&D spending and a net loss of $23.8M, driven by clinical trial expansion for lead oncology programs. The company completed an IPO in August, raising $151.7M, and expects current funds to support operations into Q2 2028.Original document: BlossomHill Therapeutics, Inc. [BLSM] SEC 10-Q Quarterly Report — Sep. 18 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 saw increased R&D spending and a net loss of $23.8M, driven by clinical trial expansion for lead oncology programs. The company completed an IPO in August, raising $151.7M, and expects current funds to support operations into Q2 2028.
Original document: BlossomHill Therapeutics, Inc. [BLSM] SEC 10-Q Quarterly Report — Sep. 18 2026